Jan Wysocki

List of Publications by Year in descending order

33 papers	2,951 citations	257101 24 h-index	395343 33 g-index
33 all docs	33 docs citations	33 times ranked	3883 citing authors

#	Article	IF	Citations
1	Glomerular Localization and Expression of Angiotensin-Converting Enzyme 2 and Angiotensin-Converting Enzyme: Implications for Albuminuria in Diabetes. Journal of the American Society of Nephrology: JASN, 2006, 17, 3067-3075.	3.0	439
2	Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?. Clinical Science, 2020, 134, 543-545.	1.8	369
3	Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2. Hypertension, 2010, 55, 90-98.	1.3	273
4	ACE and ACE2 Activity in Diabetic Mice. Diabetes, 2006, 55, 2132-2139.	0.3	270
5	Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent. Hypertension, 2020, 75, 173-182.	1.3	155
6	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor. Hypertension, 2020, 76, 1339-1349.	1.3	147
7	Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney International, 2012, 81, 520-528.	2.6	105
8	Angiotensin-Converting Enzyme 2â€“Independent Action of Presumed Angiotensin-Converting Enzyme 2 Activators. Hypertension, 2014, 63, 774-782.	1.3	101
9	Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney International, 2012, 82, 292-303.	2.6	98
10	Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 1941-1943.	3.0	95
11	Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney International, 2018, 94, 114-125.	2.6	94
12	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nature Communications, 2022, 13, 405.	5.8	92
13	Murine Recombinant Angiotensin-Converting Enzyme 2. Hypertension, 2012, 60, 730-740.	1.3	89
14	A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. Journal of the American Society of Nephrology: JASN, 2021, 32, 795-803.	3.0	82
15	Regulation of urinary ACE2 in diabetic mice. American Journal of Physiology - Renal Physiology, 2013, 305, F600-F611.	1.3	60
16	ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney. Physiological Reports, 2014, 2, e00264.	0.7	58
17	Angiotensin-converting enzyme 2 amplification limitedÂto the circulation does not protect miceÂfromÂdevelopment of diabetic nephropathy. Kidney International, 2017, 91, 1336-1346.	2.6	49
18	The ACE2â€deficient mouse: A model for a cytokine stormâ€driven inflammation. FASEB Journal, 2020, 34, 10505-10515.	0.2	41

#	Article	IF	Citations
19	Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II. Journal of Molecular Medicine, 2017, 95, 473-486.	1.7	40
20	Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System. Biomolecules, 2019, 9, 886.	1.8	39
21	Urinary Renin in Patients and Mice With Diabetic Kidney Disease. Hypertension, 2019, 74, 83-94.	1.3	33
22	An update on ACE2 amplification and its therapeutic potential. Acta Physiologica, 2021, 231, e13513.	1.8	33
23	Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease. American Journal of Physiology - Renal Physiology, 2017, 313, F487-F494.	1.3	32
24	Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis. American Journal of Hypertension, 2015, 28, 1418-1426.	1.0	28
25	A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection. Journal of the American Society of Nephrology: JASN, 2022, 33, 1293-1307.	3.0	26
26	Angiotensin-converting enzyme 2: Possible role in hypertension and kidney disease. Current Hypertension Reports, 2008, 10, 70-77.	1.5	17
27	A Fluorometric Method of Measuring Carboxypeptidase Activities for Angiotensin II and Apelin-13. Scientific Reports, 2017, 7, 45473.	1.6	17
28	Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?. Nephrology Dialysis Transplantation, 2013, 28, 2200-2202.	0.4	14
29	ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery. Clinical Science, 2020, 134, 2791-2805.	1.8	14
30	Apelinergic system in the kidney: implications for diabetic kidney disease. Physiological Reports, 2018, 6, e13939.	0.7	13
31	Urinary Angiotensinogen: A Promising Biomarker of AKI Progression in Acute Decompensated Heart Failure: What Does It Mean?. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1515-1517.	2.2	11
32	Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus. Physiological Reports, 2019, 7, e14242.	0.7	10
33	Angiotensins and the Heart. Hypertension, 2015, 66, 260-262.	1.3	7